

GenCore version 5.1.6  
Copyright (c) 1993 - 2003 Compugen Ltd.

OM nucleic - nucleic search, using sw model

Run on: October 21, 2003, 21:42:32 ; Search time 175.113 Seconds  
(without alignments)  
323.724 Million cell updates/sec

Title: US-10-071-411-6

Perfect score: 21

Sequence: 1 tcattgacgcattagagact 21

Scoring table: IDENTITY\_NUC

Gapop 10.0 , Gapext 1.0

Searched: 2552756 seqs, 1349719017 residues

Total number of hits satisfying chosen parameters: 5105512

Minimum DB seq length: 0

Maximum DB seq length: 2000000000

Post-processing: Minimum Match 0%

Maximum Match 100%

Listing first 45 summaries

Database :

N\_Geneseq\_19Jun03:\*

- 1: /SIDS1/gcgdata/geneseq/geneseq-emb1/NA1980.DAT.\*
- 2: /SIDS1/gcgdata/geneseq/geneseq-emb1/NA1981.DAT.\*
- 3: /SIDS1/gcgdata/geneseq/geneseq-emb1/NA1982.DAT.\*
- 4: /SIDS1/gcgdata/geneseq/geneseq-emb1/NA1983.DAT.\*
- 5: /SIDS1/gcgdata/geneseq/geneseq-emb1/NA1984.DAT.\*
- 6: /SIDS1/gcgdata/geneseq/geneseq-emb1/NA1985.DAT.\*
- 7: /SIDS1/gcgdata/geneseq/geneseq-emb1/NA1986.DAT.\*
- 8: /SIDS1/gcgdata/geneseq/geneseq-emb1/NA1987.DAT.\*
- 9: /SIDS1/gcgdata/geneseq/geneseq-emb1/NA1988.DAT.\*
- 10: /SIDS1/gcgdata/geneseq/geneseq-emb1/NA1989.DAT.\*
- 11: /SIDS1/gcgdata/geneseq/geneseq-emb1/NA1990.DAT.\*
- 12: /SIDS1/gcgdata/geneseq/geneseq-emb1/NA1991.DAT.\*
- 13: /SIDS1/gcgdata/geneseq/geneseq-emb1/NA1992.DAT.\*
- 14: /SIDS1/gcgdata/geneseq/geneseq-emb1/NA1993.DAT.\*
- 15: /SIDS1/gcgdata/geneseq/geneseq-emb1/NA1994.DAT.\*
- 16: /SIDS1/gcgdata/geneseq/geneseq-emb1/NA1995.DAT.\*
- 17: /SIDS1/gcgdata/geneseq/geneseq-emb1/NA1996.DAT.\*
- 18: /SIDS1/gcgdata/geneseq/geneseq-emb1/NA1997.DAT.\*
- 19: /SIDS1/gcgdata/geneseq/geneseq-emb1/NA1998.DAT.\*
- 20: /SIDS1/gcgdata/geneseq/geneseq-emb1/NA1999.DAT.\*
- 21: /SIDS1/gcgdata/geneseq/geneseq-emb1/NA2000.DAT.\*
- 22: /SIDS1/gcgdata/geneseq/geneseq-emb1/NA2001A.DAT.\*
- 23: /SIDS1/gcgdata/geneseq/geneseq-emb1/NA2001B.DAT.\*
- 24: /SIDS1/gcgdata/geneseq/geneseq-emb1/NA2002.DAT.\*
- 25: /SIDS1/gcgdata/geneseq/geneseq-emb1/NA2003.DAT.\*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

#### SUMMARIES

Result No.	Score	Query Match	Length	ID	Description
1	21	100.0	21	ABT11118	Human 5-lipoxygenase
2	21	100.0	2177	AA788433	Human 5-lipoxygenase
3	21	100.0	2183	AA788432	Human 5-lipoxygenase
4	21	100.0	2189	AA788431	Human 5-lipoxygenase
5	21	100.0	2189	ABT11113	Human 5-lipoxygenase
6	21	100.0	2189	ABD24657	Human 5-lipoxygenase
7	21	100.0	2195	AA788434	Human 5-lipoxygenase
8	21	100.0	168174	ABT111173	Human 5-lipoxygenase

9	21	100.0	168273	24	ABT11114
10	20.6	98.1	21	24	ABT111176
c 11	16.8	80.0	414	25	ABX60791
c 12	16.8	80.0	562	25	ABX57043
c 13	16.8	80.0	933	21	AA788431
c 14	16.8	80.0	935	21	AA788431
c 15	16.8	80.0	2734	17	AA788431
c 16	16.2	77.1	384	22	AA788431
c 17	16.2	77.1	394	22	AA788431
c 18	16.2	77.1	413	25	AA788431
c 19	16.2	77.1	768	22	AA788431
c 20	16.2	77.1	11980	22	AA788431
c 21	16.2	77.1	13249	24	ABT11118
c 22	16.2	77.1	13249	24	ABT11118
c 23	16.2	77.1	13249	24	ABT11118
c 24	16.2	77.1	13249	24	ABT11118
c 25	16.2	77.1	13249	24	ABT11118
c 26	16.2	77.1	13249	24	ABT11118
c 27	16.2	77.1	16532	22	AA788431
c 28	16.2	77.1	16532	22	AA788431
c 29	16	76.2	444	24	ABT11118
c 30	15.8	75.2	605	21	AA788431
c 31	15.8	75.2	2484	24	ABT11118
c 32	15.8	75.2	34337	24	ABT11118
c 33	15.8	75.2	269223	22	AA788431
c 34	15.4	73.3	1470	23	AA788431
c 35	15.4	73.3	40359	23	AA788431
c 36	15.2	72.4	171	24	ABT11118
c 37	15.2	72.4	207	21	AA788431
c 38	15.2	72.4	407	24	ABT11118
c 39	15.2	72.4	561	24	ABT11118
c 40	15.2	72.4	564	22	AA788431
c 41	15.2	72.4	2649	24	ABT11118
c 42	15.2	72.4	2999	24	ABT11118
c 43	15.2	72.4	3059	20	AA788431
c 44	15.2	72.4	3879	24	ABT11118
c 45	15.2	72.4	4215	24	ABT11118

#### ALIGNMENTS

RESULT 1

ABT11118  
ID ABT11118 standard; DNA; 21 BP.

XX AC ABT11118;

XX DT 05-DEC-2002 (first entry)

XX DE Human 5-lipoxygenase gene related DNA sequence SEQ ID No 6.

XX KW Human; polymorphic region; 5-lipoxygenase; 5-LO gene; asthma; bronchitis;  
XX KW sinusitis; ulcerative colitis; nephritis; amyloidosis; sarcoidosis;  
XX KW rheumatoid arthritis; scleroderma; lupus; non-allergic rhinitis;  
XX KW polymyositis; Reiter's syndrome; psoriasis; pelvic inflammatory disease;  
XX KW atopic; contact dermatitis; forensic medicine; paternity testing; enzyme;  
XX ds.

XX OS Homo sapiens.

XX PN WO200262825-A2.

XX PD 15-AUG-2002.

XX PF 07-FEB-2002; 2002WO-US03546.

XX PR 08-FEB-2001; 2001US-267515P.

XX PR 21-AUG-2001; 2001US-314248P.

XX PA (MILL-) MILLENNIUM PHARM INC.

XX XX Barnes G, Meyer J;

XX WPI; 2002-627522/67.  
 XX  
 PT New isolated nucleic acid molecule with an allelic variant of a  
 PT polymorphic region of an 5-LO gene, useful for diagnosing and/or  
 PT prognosticating disorders associated with an aberrant inflammatory  
 PT response such as asthma  
 XX  
 PS Claim 1; Page 235; 290pp; English.  
 XX  
 CC The invention relates to an isolated human nucleic acid molecule  
 CC comprising an allelic variant of a polymorphic region of a 5-lipoxygenase  
 CC (5-LO) gene, where the allelic variant comprises one or more nucleotide  
 CC selected from any of 3, 20 or 21 base pair sequences, given in the  
 CC specification, or their complement. The compositions and methods of the  
 CC present invention are useful for diagnosing and/or prognosing disorders  
 CC associated with an aberrant inflammatory response such as asthma,  
 CC bronchitis, sinusitis, ulcerative colitis, nephritis, amyloidosis,  
 CC rheumatoid arthritis, sarcoidosis, scleroderma, lupus, non-allergic  
 CC rhinitis, polymyositis, Reiter's syndrome, psoriasis, pelvic inflammatory  
 CC disease, atopic and contact dermatitis. The nucleic acid molecules can  
 CC also be useful for identifying an individual amongst other individuals  
 CC from the same species for use in forensic medicine and paternity testing.  
 CC This polynucleotide sequence represents DNA relating to the human 5-  
 CC lipoxygenase (5-LO) gene of the invention.  
 XX  
 SQ Sequence 21 BP; 6 A; 4 C; 4 G; 7 T; 0 other;  
 Query Match 100.0%; Score 21; DB 24; Length 21;  
 Best Local Similarity 100.0%; Pred. No. 0.16;  
 Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;  
 QY 1 TCATGTATCCGATTAGACT 21  
 Db 1 TCATGTATCCGATTAGACT 21  
 RESULT 2  
 AAT88433  
 ID AAT88433 standard; DNA; 2177 BP.  
 AC AAT88433;  
 XX  
 XX 14-MAY-1998 (first entry)  
 XX Human 5-lipoxygenase gene polymorphism 1669 to 1680 deletion.  
 DE  
 DE Inflammatory disease; polymorphism; 5-lipoxygenase;  
 KW asthma; ulcerative colitis; bronchitis; sinusitis; psoriasis;  
 KW rhinitis; arthritis; diagnosis; treatment; ds.  
 XX  
 OS Homo sapiens.  
 OS Synthetic.  
 XX  
 PN WO9742347-A2  
 XX  
 PD 13-NOV-1997.  
 XX  
 XX 29-APR-1997; 97WO-US07137.  
 XX  
 XX 25-APR-1997; 97US-0846020.  
 PR  
 PR 06-MAY-1996; 96US-0016890.  
 XX  
 XX (BGHM ) BRIGHAM & WOMENS HOSPITAL.  
 XX  
 XX Asano K, Beier D, Drazen JM, Grobholz J, In K;  
 PI WPI; 1997-558997/51.  
 DR  
 XX Classifying patients with inflammatory disease, specifically asthma  
 PT - according to polymorphisms in 5-lipoxygenase gene regulatory  
 PT region, e.g. to identify candidates for lipoxygenase inhibitor  
 PT treatment

XX Claim 13; Page -; 56pp; English.  
 XX  
 CC The present sequence was used in the development of a novel method  
 CC for classifying patients suffering from an inflammatory disease.  
 CC The method comprises identifying in DNA from at least 1 patient a  
 CC sequence polymorphism, as compared with the normal 5-lipoxygenase  
 CC (5-LOX) gene (AAT88431), in a 5-LOX regulatory gene sequence.  
 CC The method can be applied to subjects with asthma, ulcerative  
 CC colitis, bronchitis, sinusitis, psoriasis, allergic and  
 CC non-allergic rhinitis, lupus or rheumatoid arthritis. Specifically  
 CC it can be used to diagnose asthma or susceptibility to disease,  
 CC identify treatments suitable for individual patients or assess the  
 CC likely success of treatment.  
 CC N.B. Sequence not given in the specification, but constructed  
 CC using the wild type human 5-lipoxygenase gene sequence given on  
 CC pages 40 to 41.  
 XX  
 SQ Sequence 2177 BP; 541 A; 597 C; 654 G; 385 T; 0 other;  
 Query Match 100.0%; Score 21; DB 18; Length 2177;  
 Best Local Similarity 100.0%; Pred. No. 0.26;  
 Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;  
 QY 1 TCATGTATCCGATTAGACT 21  
 Db 549 TCATGTATCCGATTAGACT 569  
 RESULT 3  
 AAT88432  
 ID AAT88432 standard; DNA; 2183 BP.  
 XX  
 AC AAT88432;  
 XX  
 XX 14-MAY-1998 (first entry)  
 XX Human 5-lipoxygenase gene polymorphism 1669 to 1674 deletion.  
 DE  
 DE Inflammatory disease; polymorphism; 5-lipoxygenase;  
 KW asthma; ulcerative colitis; bronchitis; sinusitis; psoriasis;  
 KW rhinitis; arthritis; diagnosis; treatment; ds.  
 XX  
 OS Homo sapiens.  
 OS Synthetic.  
 XX  
 PN WO9742347-A2.  
 XX  
 PD 13-NOV-1997.  
 XX  
 XX 29-APR-1997; 97WO-US07137.  
 XX  
 XX 25-APR-1997; 97US-0846020.  
 PR  
 PR 06-MAY-1996; 96US-0016890.  
 XX  
 XX (BGHM ) BRIGHAM & WOMENS HOSPITAL.  
 XX  
 XX Asano K, Beier D, Drazen JM, Grobholz J, In K;  
 PI WPI; 1997-558997/51.  
 DR  
 XX Classifying patients with inflammatory disease, specifically asthma  
 PT - according to polymorphisms in 5-lipoxygenase gene regulatory  
 PT region, e.g. to identify candidates for lipoxygenase inhibitor  
 PT treatment  
 XX  
 PS Claim 12; Page -; 56pp; English.  
 XX  
 CC The present sequence was used in the development of a novel method  
 CC for classifying patients suffering from an inflammatory disease.  
 CC The method comprises identifying in DNA from at least 1 patient a  
 CC sequence polymorphism, as compared with the normal 5-lipoxygenase  
 CC (5-LOX) gene (AAT88431), in a 5-LOX regulatory gene sequence.

CC The method can be applied to subjects with asthma, ulcerative  
 CC colitis, bronchitis, sinusitis, psoriasis, allergic and  
 CC non-allergic rhinitis, lupus or rheumatoid arthritis. Specifically  
 CC it can be used to diagnose asthma or rheumatoid arthritis to disease,  
 CC identify treatments suitable for individual patients or assess the  
 CC likely success of treatment.  
 CC N.B. Sequence not given in the specification, but constructed  
 CC using the wild type human 5-lipoxygenase gene sequence given on  
 CC pages 40 to 41.

XX Sequence 2183 BP; 541 A; 598 C; 659 G; 385 T; 0 other;

Query Match 100.0%; Score 21; DB 18; Length 2183;  
 Best Local Similarity 100.0%; Pred. No. 0.22;  
 Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 AGGAGCGCGGAAACCTTCTC 21  
 DB 990 AGGAGCGCGGAAACCTTCTC 1010

## RESULT 4

AAAT88431  
 ID AAAT88431 standard; DNA; 2189 BP.

XX AAAT88431;

XX 14-MAY-1998 (first entry)

DE Human 5-lipoxygenase gene.

XX Inflammatory disease; polymorphism; 5-lipoxygenase;  
 KW asthma; ulcerative colitis; bronchitis; sinusitis; psoriasis;  
 KW rhinitis; arthritis; diagnosis; treatment; ds.

XX Homo sapiens.

XX WO9742347-A2.

XX 13-NOV-1997.

XX 29-APR-1997; 97WO-US07137.

XX 25-APR-1997; 97US-0846020.

XX 06-MAY-1996; 96US-0016890.

XX (BGHM) BRIGHAM & WOMENS HOSPITAL.

XX Asano K, Beier D, Drazen JM, Grobholz J, In K;

XX WPI; 1997-558997/51.

XX Classifying patients with inflammatory disease, specifically asthma  
 PT - according to polymorphisms in 5-lipoxygenase gene regulatory  
 PT region, e.g. to identify candidates for lipoxygenase inhibitor  
 PT treatment

XX Claim 11; Pages 40-41; 56pp; English.

XX The present sequence was used in the development of a novel method  
 CC for classifying patients suffering from an inflammatory disease.  
 CC The method comprises identifying in DNA from at least 1 patient a  
 CC sequence polymorphism, as compared with the normal 5-lipoxygenase  
 CC (5-LOX) gene (AAAT88431), in a 5-LOX regulatory gene sequence.  
 CC The method can be applied to subjects with asthma, ulcerative  
 CC colitis, bronchitis, sinusitis, psoriasis, allergic and  
 CC non-allergic rhinitis, lupus or rheumatoid arthritis. Specifically  
 CC it can be used to diagnose asthma or susceptibility to disease,  
 CC identify treatments suitable for individual patients or assess the  
 CC likely success of treatment.

XX Sequence 2189 BP; 541 A; 599 C; 664 G; 385 T; 0 other;

Query Match 100.0%; Score 21; DB 18; Length 2189;  
 Best Local Similarity 100.0%; Pred. No. 0.22;  
 Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 AGGAGCGCGGAAACCTTCTC 21  
 DB 990 AGGAGCGCGGAAACCTTCTC 1010

## RESULT 5

ABT11113  
 ID ABT11113 standard; DNA; 2189 BP.

XX ABT11113;

XX 05-DEC-2002 (first entry)

DE Human 5-lipoxygenase gene related DNA sequence SEQ ID No 1.

XX Human; polymorphic region; 5-lipoxygenase; 5-LO gene; asthma; bronchitis;  
 KW sinusitis; ulcerative colitis; nephritis; amyloidosis; sarcoidosis;  
 KW rheumatoid arthritis; scleroderma; lupus; non-allergic rhinitis;  
 KW polymyositis; Reiter's syndrome; psoriasis; pelvic inflammatory disease;  
 KW atopic; contact dermatitis; forensic medicine; paternity testing; enzyme;  
 KW ds.

XX Homo sapiens.

XX WO200262825-A2.

XX 15-AUG-2002.

XX 07-FEB-2002; 2002WO-US03546.

XX 08-FEB-2001; 2001US-267515P.

XX 21-AUG-2001; 2001US-314248P.

XX (MILL-) MILLENNIUM PHARM INC.

XX Barnes G, Meyer J;

XX WPI; 2002-627522/67.

XX New isolated nucleic acid molecule with an allelic variant of a  
 PT polymorphic region of an 5-LO gene, useful for diagnosing and/or  
 PT prognosticating disorders associated with an aberrant inflammatory  
 PT response such as asthma

XX Claim 6; Fig 1; 290pp; English.

XX The invention relates to an isolated human nucleic acid molecule  
 CC comprising an allelic variant of a polymorphic region of a 5-lipoxygenase  
 CC (5-LO) gene, where the allelic variant comprises one or more nucleotide  
 CC selected from any of 3, 20 or 21 base pair sequences, given in the  
 CC specification, or their complement. The compositions and methods of the  
 CC present invention are useful for diagnosing and/or prognosticating disorders  
 CC associated with an aberrant inflammatory response such as asthma,  
 CC bronchitis, sinusitis, ulcerative colitis, nephritis, amyloidosis,  
 CC rheumatoid arthritis, sarcoidosis, scleroderma, lupus, non-allergic  
 CC rhinitis, polymyositis, Reiter's syndrome, psoriasis, pelvic inflammatory  
 CC disease, atopic and contact dermatitis. The nucleic acid molecules can  
 CC also be useful for identifying an individual amongst other individuals  
 CC from the same species for use in forensic medicine and paternity testing.  
 CC This polynucleotide sequence represents DNA relating to the human 5-  
 CC lipoxygenase (5-LO) gene of the invention.

XX Sequence 2189 BP; 541 A; 599 C; 664 G; 385 T; 0 other;

Query Match 100.0%; Score 21; DB 24; Length 2189;  
 Best Local Similarity 100.0%; Pred. No. 0.22;  
 Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 AGGAGCGCGGAAACCTTCTC 21

Db 990 AGGAGCGCGGAAACCTTCTC 1010  
|||||

## RESULT 6

AAD24657  
ID AAD24657 standard; DNA; 2189 BP.

XX AC AAD24657;

XX DT 12-MAR-2002 (first entry)

XX DE Human 5-lipoxygenase (ALOX5) gene partial coding sequence.

XX KW Human; 5-lipoxygenase; ALOX5; respiratory disease; therapy;

XX KW asthma; leukotriene receptor antagonist; ds.

XX OS Homo sapiens.

XX FH Key Location/Qualifiers  
repeat\_region 1669..1698

XX FT /\*tag= a

XX FT /rpt\_type= TANDEM

XX FT repeat\_unit 1669..1675

XX FT /\*tag= b

XX FT /note= "Sp1 binding motif (GGGCGG)"

XX FT misc\_signal 1845..1847

XX FT /\*tag= c

XX FT /note= "Translation start site"

XX PN WO200179560-A2.

XX XX 25-OCT-2001.

XX XX 17-APR-2001; 2001WO-US12534.

XX XX 17-APR-2000; 2000US-197913P.

XX PR 29-SEP-2000; 2000US-236608P.

XX XX (GLAX ) GLAXO GROUP LTD.

XX PI Anderson WH, Edwards LD, Emmett AH, Pillai S, Sprankel CS;

XX DR WPI; 2002-066375/09.

XX PT Screening a subject suffering from a respiratory disease that can be treated with a leukotriene receptor antagonist, by determining the genotype of the DNA at a polymorphic allele site in the 5-lipoxygenase gene and LTC4 synthase gene -

XX PS Example 1; Page 12-13; 67pp; English.

XX CC The invention relates to a method of screening a subject suffering from a respiratory disease which can be treated with a leukotriene receptor antagonist. The method comprises determining the genotype of the DNA at a polymorphic allele site in the 5-lipoxygenase gene and a polymorphic allelic site in the LTC4 synthase gene, where different genotypes at these sites are associated with different incidences of a phenotypic response to the treatment. The method is useful for screening a subject suffering from a respiratory disease, which can be treated with a leukotriene receptor antagonist, particularly asthma, as an aid in predicting the subject's response to the treatment. The present sequence is human 5-lipoxygenase (ALOX5) gene partial coding sequence.

XX SQ Sequence 2189 BP; 541 A; 599 C; 664 G; 385 T; 0 other;

Query Match 100.0%; Score 21; DB 24; Length 2189;

Best Local Similarity 100.0%; Pred. No. 0.22;

Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 AGGAGCGCGGAAACCTTCTC 21

Db 990 AGGAGCGCGGAAACCTTCTC 1010

## RESULT 7

AAT88434  
ID AAT88434 standard; DNA; 2195 BP.

XX AC AAT88434;

XX DT 14-MAY-1998 (first entry)

XX DE Human 5-lipoxygenase gene polymorphism 1688 (GGGCGG) 6 bp addition.

XX KW Inflammatory disease; polymorphism; 5-lipoxygenase;

XX KW asthma; ulcerative colitis; bronchitis; sinusitis; psoriasis;

XX KW rhinitis; arthritis; diagnosis; treatment; ds.

XX OS Homo sapiens.

XX OS Synthetic.

XX XX WO9742347-A2.

XX PN 13-NOV-1997.

XX XX 29-APR-1997; 97WO-US07137.

XX XX 25-APR-1997; 97US-0845020.

XX PR 06-MAY-1996; 96US-0016890.

XX XX (BGHM ) BRIGHAM & WOMENS HOSPITAL.

XX PI Asano K, Beier D, Drazen JM, Grobholz J, In K;

XX DR WPI; 1997-558997/51.

XX PT Classifying patients with inflammatory disease, specifically asthma - according to polymorphisms in 5-lipoxygenase gene regulatory region, e.g. to identify candidates for lipoxygenase inhibitor treatment

XX PS Claim 15; Page -; 56pp; English.

XX CC The present sequence was used in the development of a novel method for classifying patients suffering from an inflammatory disease. The method comprises identifying in DNA from at least 1 patient a sequence polymorphism, as compared with the normal 5-lipoxygenase (5-LOX) gene (AAT88431), in a 5-LOX regulatory gene sequence. The method can be applied to subjects with asthma, ulcerative colitis, bronchitis, sinusitis, psoriasis, allergic and non-allergic rhinitis, lupus or rheumatoid arthritis. Specifically it can be used to diagnose asthma or susceptibility to disease, identify treatments suitable for individual patients or assess the likely success of treatment.

XX CC N.B. Sequence not given in the specification, but constructed using the wild type human 5-lipoxygenase gene sequence given on pages 40 to 41.

XX SQ Sequence 2195 BP; 541 A; 600 C; 669 G; 385 T; 0 other;

Query Match 100.0%; Score 21; DB 18; Length 2195;

Best Local Similarity 100.0%; Pred. No. 0.22;

Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 AGGAGCGCGGAAACCTTCTC 21

Db 990 AGGAGCGCGGAAACCTTCTC 1010

## RESULT 8

ABT11173

ID ABT11173 standard; DNA; 168174 BP.

XX AC ABT11173;

XX XX